If you are dealing with joint pain, tendon injuries, or early arthritis, you have likely encountered three main injection-based treatment options: cortisone (corticosteroid) injections, platelet-rich plasma (PRP), and mesenchymal stem cell (MSC) therapy. Each has a different mechanism, evidence base, cost profile, and appropriate use case. Understanding these differences prevents you from either overpaying for unnecessary treatment or missing a more effective option.
Cortisone provides fast but temporary relief with potential long-term downsides. PRP offers moderate regenerative benefit at moderate cost. MSC therapy has the highest regenerative potential but the highest cost and the most variable evidence depending on the condition. The right choice depends on your diagnosis, disease severity, and treatment goals.
Head-to-Head Comparison
| Factor | Cortisone | PRP | MSC Stem Cells |
|---|---|---|---|
| Mechanism | Anti-inflammatory (suppresses immune response) | Growth factor delivery (concentrated from your blood) | Paracrine signaling + immunomodulation + limited tissue repair |
| Evidence Level | Level 1 (well-established) | Level 2 (good evidence for some indications) | Level 2-3 (moderate, growing) |
| Onset of relief | 24–72 hours | 2–6 weeks | 4–12 weeks |
| Duration of effect | 4–12 weeks (diminishing returns) | 6–12 months | 12–24+ months |
| Repeated use concerns | Yes — potential cartilage damage with >3-4 injections/year | Safe to repeat | Safe to repeat (booster at 12-18 months common) |
| US cost per injection | $150–$500 (often insurance-covered) | $500–$1,500 (rarely covered) | $5,000–$15,000 (never covered) |
| Colombia cost | $50–$150 | $200–$600 | $3,500–$8,500 |
| Best for | Acute flares, diagnostic confirmation | Mild OA, tendinopathy, sports injuries | Moderate OA, failed PRP, wanting to delay surgery |
Cortisone: Fast Relief, Diminishing Returns
Cortisone injections are the most established treatment. They work by suppressing inflammation in the joint, providing rapid pain relief — often within 24–72 hours. However, cortisone does not address the underlying disease process and has diminishing effectiveness with repeated injections. Concerning evidence suggests that repeated cortisone injections may actually accelerate cartilage breakdown in osteoarthritic joints over time. Most orthopedic guidelines recommend limiting cortisone to three to four injections per year per joint.
Cortisone remains appropriate for acute flares (rapid pain control), diagnostic purposes (if the injection provides relief, it confirms the joint as the pain source), and patients who need short-term function for a specific event or activity.
PRP: The Middle Ground
Multiple RCTs show PRP is superior to cortisone and hyaluronic acid for knee OA at 12-month follow-up. Evidence is strongest for mild-to-moderate OA and tendinopathy. PRP preparation protocols vary significantly between clinics, which affects outcomes.
PRP is prepared from your own blood. A blood draw (typically 30–60ml) is centrifuged to concentrate platelets, which contain growth factors that promote tissue healing. The concentrated plasma is injected into the affected joint or tendon under ultrasound guidance. Because PRP uses your own biological material, there are essentially no rejection or allergy risks.
PRP occupies a useful middle position: more regenerative potential than cortisone, lower cost and more established evidence than MSC therapy. For patients with early-stage OA or tendinopathy who have not responded to conservative measures but are not ready for the cost and commitment of stem cell therapy, PRP is often the most appropriate next step.
MSC Stem Cells: Highest Potential, Highest Investment
MSC therapy delivers cells that actively modulate the joint environment — reducing inflammation, releasing growth factors, and potentially stimulating limited tissue repair. The biological activity of MSCs exceeds what PRP alone can deliver, which is reflected in published outcomes showing superior and more durable pain relief for moderate OA.
The key question is whether the additional benefit justifies the additional cost. For patients with Kellgren-Lawrence Grade 1-2 OA, PRP may provide sufficient relief. For Grade 2-3 OA, where the disease is more advanced but total knee replacement is premature, MSC therapy offers a stronger intervention. For Grade 4, neither PRP nor MSC therapy is likely to avoid eventual joint replacement — though MSC therapy may provide meaningful pain reduction and delay surgery.
A Rational Treatment Ladder
Rather than choosing one treatment in isolation, most regenerative medicine specialists recommend a stepped approach. Start with conservative measures (physical therapy, weight management, bracing). Try cortisone for acute flares if needed. Progress to PRP for sustained improvement. Consider MSC therapy if PRP provides insufficient relief and the alternative is joint replacement.
Colombia's pricing advantage is most impactful at the MSC level, where the US cost ($5,000–$15,000+) is a significant barrier. At $3,500–$8,500 in Colombia, MSC therapy becomes accessible to patients who could never afford it domestically — potentially delaying or avoiding a knee replacement that would cost $40,000–$60,000 in the US.
There is no single "best" injection therapy. The right choice depends on your disease stage, prior treatment response, budget, and goals. A responsible clinic — in Colombia or anywhere — will recommend the least invasive, most evidence-supported option that matches your situation, not the most expensive one on their menu.
Explore Stem Cell Treatment in Colombia
Connect with INVIMA-regulated clinics for a free consultation. Evidence-based information, transparent pricing, no pressure.
Chat With Us on WhatsApp